Other active comparator
Additional oad
OTHER_ACTIVE_additional_OAD
Related
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.39 (0.00 to 28.94) | 0.50 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.41 (0.01 to 25.34) | 0.44 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.65 (0.09 to 3.73) | 0.59 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.59 (0.07 to 4.14) | 0.63 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD 0.73 (-4.13 to 5.59) | 0.17 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD -0.15 (-6.64 to 6.26) | 0.30 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.96 (0.41 to 2.07) | 0.51 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.91 (0.36 to 2.03) | 0.55 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.77 (0.22 to 2.18) | 0.72 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.81 (0.22 to 2.58) | 0.67 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.16 (0.02 to 0.70) | 0.94 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.18 (0.02 to 0.91) | 0.87 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.69 (0.11 to 2.49) | 0.80 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.82 (0.12 to 3.67) | 0.70 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.92 (0.37 to 1.93) | 0.73 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.02 (0.40 to 2.30) | 0.63 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.44 (0.14 to 1.09) | 0.83 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.52 (0.18 to 1.34) | 0.75 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 0.11 (0.00 to 1.31) | 0.87 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 0.11 (0.00 to 1.22) | 0.83 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.80 (0.04 to 11.62) | 0.49 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.74 (0.05 to 11.51) | 0.42 |
| Type 2 diabetes (adults) | Any cancer | longest follow-up | Placebo | HR 1.82 (0.19 to 13.12) | 0.36 |
| Type 2 diabetes (adults) | Any cancer | longest follow-up | Placebo | HR 2.07 (0.20 to 16.28) | 0.36 |